Quince Therapeutics, Inc.
QNCX
$34.04
$1.635.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 35.91M | -39.46M | -13.44M | -16.05M | -15.03M |
| Total Depreciation and Amortization | 36.00K | 39.00K | 36.00K | 35.00K | 32.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -41.20M | 16.47M | 3.28M | 6.47M | 3.35M |
| Change in Net Operating Assets | -2.38M | 12.47M | 194.00K | -1.87M | 2.05M |
| Cash from Operations | -7.63M | -10.48M | -9.93M | -11.42M | -9.60M |
| Capital Expenditure | -- | -4.00K | -74.00K | -126.00K | -148.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.00M | 8.08M | -1.71M | 6.17M | 11.05M |
| Cash from Investing | 12.00M | 8.07M | -1.78M | 6.04M | 10.90M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -5.55M | -- | -- | -- | -- |
| Issuance of Common Stock | 14.99M | 2.03M | 1.38M | 14.41M | 87.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 9.44M | 2.03M | 1.38M | 14.41M | 87.00K |
| Foreign Exchange rate Adjustments | -1.46M | -267.00K | -41.00K | 19.00K | 175.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.35M | -643.00K | -10.37M | 9.06M | 1.56M |